All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ASC41
Therapeutic Area: Cardiology/Vascular Diseases Product Name: ASC41
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 22, 2020
Details:
The trial aims to evaluate 1) the impact of ASC41 on markers of cardiac health; 2) the safety and tolerability of ASC41 tablets; 3) the pharmacokinetics of ASC41 tablets and its active moiety, ASC41-A, in overweight and obese subjects.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): DTRI-031
Therapeutic Area: Cardiology/Vascular Diseases Product Name: DTRI-031
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Rev1 Ventures
Deal Size: $5.4 million Upfront Cash: Undisclosed
Deal Type: Financing December 07, 2020
Details:
The Company’s development candidate, DTRI-031, is an RNA aptamer that inhibits von Willebrand Factor (vWF). Basking is co-developing a matched oligonucleotide reversal agent, DTRI-025, for as-needed, rapid reversal of DTRI-031.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): SEFA-1024
Therapeutic Area: Cardiology/Vascular Diseases Product Name: SEFA-1024
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 20, 2020
Details:
SEFA-1024 is a novel chemically modified fatty acid derived from naturally occurring fatty acid EPA. Phase 1 trial will evaluate the safety, tolerability, and pharmacokinetics of SEFA-1024 in 96 otherwise healthy volunteers with high plasma triglyceride levels.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): SLN360
Therapeutic Area: Cardiology/Vascular Diseases Product Name: SLN360
Highest Development Status: Phase I Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2020
Details:
Results presented show that the distribution of SLN360 is confined to the liver (target organ) and kidney (route of elimination) as intended, with levels of SLN360 in other organs (including reproductive organs) less than 1% of peak liver levels.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ARO-ANG3
Therapeutic Area: Cardiology/Vascular Diseases Product Name: ARO-ANG3
Highest Development Status: Phase I Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 13, 2020
Details:
Arrowhead Pharmaceuticals to present positive clinical data from multiple product candidates in its cardiometabolic pipeline which includes ARO-APOC3, ARO-ANG3 and AMG 890.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ALN-AGT
Therapeutic Area: Cardiology/Vascular Diseases Product Name: ALN-AGT
Highest Development Status: Phase I Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 13, 2020
Details:
Patients receiving investigational ALN-AGT experienced dose-dependent reductions in blood pressure, confirming potential for rnai-mediated angiotensinogen (AGT) silencing as a novel therapeutic approach for hypertension.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CDR132L
Therapeutic Area: Cardiology/Vascular Diseases Product Name: CDR132L
Highest Development Status: Phase I Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 22, 2020
Details:
The study demonstrates that repeated treatment with its lead compound Cdr132 L is safe, improves cardiac function and reduces both ventricular as well as left atrial volumes in chronic heart failure.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CK-3772271
Therapeutic Area: Cardiology/Vascular Diseases Product Name: CK-271
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 23, 2020
Details:
CK-271 is a second cardiac myosin inhibitor, discovered by company scientists, in development for the potential treatment of hypertrophic cardiomyopathy (HCM).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): JK07
Therapeutic Area: Cardiology/Vascular Diseases Product Name: JK07
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Carlyle
Deal Size: $260.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition September 01, 2020
Details:
Salubris has developed a comprehensive innovative pipeline in the treatment of chronic diseases, including JK07, an innovative biologic drug treating heart failure which has filed for clinical trial approvals in both China and the United States.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ARO-APOC3
Therapeutic Area: Cardiology/Vascular Diseases Product Name: ARO-APOC3
Highest Development Status: Phase I Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 31, 2020
Details:
Presentation to showcase Phase 1/2 clinical data on two RNAi-based cardiometabolic candidates, ARO-APOC3 targeting apolipoprotein C-III being developed as a treatment for patients with hypertriglyceridemia, and ARO-ANG3 being developed as a treatment for mixed dyslipidemias.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
